**External request**
Submission request from Epigenomics regarding FDA PMA approved methylated SEPT9 promoter DNA test for colorectal cancer screening:

- We request that the statement regarding inferiority for CRC and adenoma detection be removed
- We request an update to the description of the SEPT9 test to reflect the correct data for the FDA approved version of the test
- We request removal of the Church et.al. study as a performance measure since it refers to an earlier version of the test prior to the PMA approved version
- We request specific consideration of the noncompliant / unscreened as part of the guideline recommendations

Based on the discussion, the panel consensus supported revising the following footnote “g” which now reads, “A blood test that detects circulating methylated SEPT9 DNA has been FDA-approved for CRC screening for those who refuse other screening modalities. It is not recommended for routine screening. The interval for repeating testing is unknown.”

Any requested revisions to the corresponding discussion would be made as appropriate when updated.

See Submission for references.